Paper Details

  1. Home
  2. Paper Details

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.

Author: ChaffinKassie R, HaberBarbara A, HillDeanna D, KanwalFasiha, KramerJennifer R, MastT Christopher, RobertsonMichael N

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Clinical trials revealed that elbasvir/grazoprevir treatment for 12 weeks led to lower sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) genotype 1a infection and baseline resistance-associated substitutions (RASs). Extending treatment duration to 16 weeks and adding ribavirin improved SVR rates in these patients.
Paper Details　
Original Abstract of the Article :
In clinical trials, patients with hepatitis C virus (HCV) genotype (GT)1a infection and baseline resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 receiving elbasvir/grazoprevir for 12 weeks achieved lower rates of sustained virologic response (SVR) than those with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.aohep.2023.100899

データ提供：米国国立医学図書館（NLM）

Elbasvir/Grazoprevir Plus Ribavirin: A New Hope for Hepatitis C Virus Genotype 1a Infection

The field of [hepatitis C virus treatment] constantly seeks new and effective therapies to combat this prevalent disease. This research focuses on the effectiveness of elbasvir/grazoprevir, a combination antiviral drug, in treating hepatitis C virus (HCV) genotype 1a infection, particularly in patients with baseline resistance-associated substitutions (RASs).

A Comprehensive Approach to Challenging Cases

The study revealed that patients with HCV genotype 1a infection and baseline RASs who received elbasvir/grazoprevir for 12 weeks achieved lower sustained virologic response (SVR) rates compared to those without RASs. However, extending the treatment duration to 16 weeks and administering ribavirin alongside the elbasvir/grazoprevir regimen significantly improved SVR rates in patients with RASs. This finding highlights the importance of tailoring treatment strategies based on individual patient characteristics and the presence of RASs.

Hope on the Horizon for Difficult Cases

This study suggests that the elbasvir/grazoprevir plus ribavirin combination could provide a viable option for managing HCV genotype 1a infection, even in challenging cases with pre-existing resistance. While this finding is encouraging, it is essential to continue researching and developing new therapies to address the ever-evolving nature of HCV infection. These efforts will pave the way for more effective and personalized treatment strategies for patients.

Dr.Camel's Conclusion

Like a resilient camel navigating a treacherous desert landscape, this research explores the potential of a specific combination therapy to conquer the challenges posed by HCV genotype 1a infection, particularly in the presence of resistance. The findings offer a beacon of hope for patients, highlighting the ongoing efforts to develop effective and personalized treatments for this complex disease.
Date :
  1. Date Completed 2023-03-20
  2. Date Revised 2023-03-20
Further Info :

Pubmed ID

36632975

DOI: Digital Object Identifier

10.1016/j.aohep.2023.100899

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.